ProBiotix Health

What ProBiotix Health does

ProBiotix Health Plc is a UK life-sciences company, founded in 2018 and headquartered in Wakefield, England, that develops probiotic formulations for cardiometabolic health. It is publicly traded on the Aquis Stock Exchange Growth Market (ticker: PBX) since 31 March 2022, having raised £2.5M at admission. The company was established by AIM-listed OptiBiotix Health plc, which remains its largest shareholder at approximately 33.85% of issued share capital, alongside other concentrated holders including Holdingsselskabet of 29. Juni 2010 Aps (~20.97%) and Seneca Partners Limited (~5.00%).

The company's technology platform centers on its proprietary probiotic strain LP-LDL® (Lactobacillus plantarum ECGC13110402), which is supported by independent clinical studies reporting reductions in total cholesterol by ~34–36%, LDL by ~28%, non-HDL cholesterol by ~17%, and apolipoprotein B by ~28%. LP-LDL® received US GRAS designation in February 2019 and is manufactured in GMP-certified facilities. The intellectual property portfolio comprises approximately 5 patent families (27 patents/applications) and 22 trademarks. Product offerings include the ingredient LP-LDL® for B2B license, the CholBiome® branded range (CholBiome®, CholBiome®X3 combining LP-LDL® with Monacolin K and niacin, CholBiome®BP for blood pressure, and CholBiome®VH for vascular health), and co-branded finished products such as CARDIObiom+® developed with iProbio.

ProBiotix operates a B2B go-to-market model, supplying its probiotic ingredient on a licensing/royalty-equivalent basis and offering turn-key or white-label finished supplements to organizations worldwide. Distribution is achieved through channel partners and regional distributors, with products commercialized in over 60 countries. For the nine months to September 2025, revenue was £1.97M, up 30% year-on-year; the company reported 2025 full-year profitability with approximately 45% revenue growth. Key named partners include iProbio (Slovakia, June 2026), RevivaBio (October 2025), and SymbioPharm (February 2024). The company employs 11–50 staff and is led by CEO Steen Andersen under Non-executive Chairman Adam Reynolds, with founder Stephen O'Hara (OptiBiotix) as a continuing significant shareholder.

Name

ProBiotix Health

Legal name

ProBiotix Health Plc

Website

https://probiotixhealth-ir.com

Company type

Public

Founded year

2018

Operating status

Operating

Headcount range

11–50 employees

Short description

ProBiotix Health is a UK-listed life-sciences company that develops clinically validated probiotic formulations, centered on its proprietary LP-LDL® strain, for B2B partners and white-label cardiometabolic health supplements distributed in over 60 countries.

Ownership category

akta.pro rank

Product category

Probiotic Nutraceutical Supplements

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Probiotics (Strains, Spore-Formers, Synbiotic Components) (AFAJAKAE)

Keywords

• Probiotic supplements
• Cardiometabolic health
• White label nutraceuticals
• Probiotic ingredients
• Cardiovascular probiotics

Headquarters

HQ city

Wakefield

HQ country

United Kingdom

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. B2B Ingredient Sales: Supply of LPLDL® probiotic ingredient to business partners who incorporate it into their own branded products.
2. White Label Product Sales: Turn-key or white label probiotic based supplements supplied to organisations worldwide under CholBiome® brand or private label.
3. CholBiome® Product Range: Finished probiotic products under CholBiome® brand including CholBiome, CholBiome®X3, CholBiome®BP, and CholBiome®VH for cardiovascular health.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels3 records

Core offering

ProBiotix Health develops and commercialises the proprietary LPLDL® probiotic strain (Lactobacillus plantarum ECGC13110402) as a B2B active ingredient for incorporation into partners' branded cardiometabolic products. The company also supplies finished turn-key or white-label probiotic-based supplements under its CholBiome® range (CholBiome®, CholBiome®X3, CholBiome®BP, CholBiome®VH) to nutraceutical organisations worldwide.

Product overview

ProBiotix Health is a life sciences company that develops probiotic formulations to support cardiometabolic health. The company has built a portfolio centered on its proprietary LPLDL® probiotic strain, which serves as the foundation for its finished product range. The core CholBiome® brand portfolio includes four distinct products: CholBiome® (cholesterol maintenance), CholBiome®X3 (triple-action cholesterol reduction), CholBiome®BP (blood pressure support), and CholBiome®VH (vascular health). Products are offered as business-to-business turn-key or white label probiotic-based supplements to organisations worldwide, with global commercial operations spanning over 60 countries. The company also enables co-branded finished products through partnerships, such as the CARDIObiom+® product with iProbio in Slovakia.

Differentiator

Problem solved

Functional benefit

Brands

• CholBiome®: Contains LP-LDL® as the only active ingredient, focused on healthy cholesterol maintenance and tangible health benefits.
• CholBiome®X3
• CholBiome®BP
• CholBiome®VH
• LPLDL®
• CARDIObiom+®

Products and services

• LPLDL®

Quantifiable outcome

• Reduces total cholesterol by 36%
• +4 more outcomes

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Three partnerships are on record, tiered core and minor.

• iProbio (PerBiotiX s.r.o.)coreChannel Partner/ Reseller/ Distributor · 1 June 2026Commercial cooperation with Slovakia-based iProbio to supply patented probiotic strain LPLDL® for CARDIObiom+® cardiometabolic health food supplement. ProBiotix supplies the active ingredient while iProbio handles manufacturing, packaging, and branding. Initial distribution in Slovakia through e-commerce, expanding to pharmacies and health food stores with further expansion planned for Czech Republic and Central European markets.
• RevivaBiocoreChannel Partner/ Reseller/ Distributor · 19 October 2025Commercial partnership formed to launch a new cholesterol-lowering probiotic product.
• SymbioPharmminorChannel Partner/ Reseller/ DistributorPartner agreement established in February 2024 for probiotic commercialisation.

Scale indicators6 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• BioGaia: Swedish probiotic company developing branded probiotic supplements backed by clinical evidence, with both B2B ingredient supply and consumer health products. Directly comparable in combining clinically validated Lactobacillus strains with a white-label and branded supplement portfolio.
• Lallemand Health Solutions: Major global probiotic strain supplier offering proprietary Lactobacillus and Bifidobacterium strains for human health applications including cardiometabolic and gut health. Directly comparable B2B ingredient model to ProBiotix's LPLDL® strain licensing business.
• AB Biotics (AB Mauri): Spanish probiotic strain developer (within AB Mauri) supplying custom probiotic solutions for food and supplement industries via a B2B model. Comparable proprietary-strain discovery and ingredient licensing approach serving nutraceutical partners globally.
• Ganeden (Kerry Group): Probiotic ingredient supplier (now part of Kerry Group) with patented Bacillus coagulans strains for food, beverage, and supplement applications. Directly comparable B2B licensing model with patented strains targeting functional food and supplement partners.
• OptiBiotix Health plc: Parent company and direct peer: develops proprietary probiotic and microbiome-based ingredients for cardiometabolic and lifestyle conditions via a B2B ingredient licensing model. Closely comparable in strain-discovery approach, clinical validation strategy, and white-label/partner-led commercialisation.

Emerging players

• Seed Health: Consumer microbiome brand combining clinical evidence with branded direct-to-consumer probiotic supplements. Comparable in pairing rigorous clinical research with a finished-product brand play, though Seed is primarily consumer-DTC while ProBiotix is B2B-led.
• Pendulum Therapeutics: Microbiome-focused company developing targeted probiotic formulations for metabolic health conditions including Type 2 diabetes. Directly overlaps with ProBiotix's cardiometabolic positioning and shares a science-led, clinically validated approach to microbiome interventions.

Broad incumbents

• Lesaffre: Global supplier of yeast and live probiotic cultures for food, nutrition, and health applications, including cardiovascular and metabolic health positioning. Broad incumbent with overlapping strain technology and ingredient-licensing business.
• ADM Protexin: Specialty probiotic ingredient business within ADM, supplying human and animal nutrition markets with proprietary probiotic strains. Broad incumbent in the probiotic B2B ingredient space with materially larger scale and distribution.
• Chr. Hansen (Novonesis): World's largest probiotic cultures supplier following the Novonesis merger, with a broad strain portfolio serving food, dairy, supplement, and pharma customers globally. Established incumbent with overlapping capabilities across ProBiotix's entire addressable market.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks7 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/watch?v=sen9YAG9gMo
• Facebookfacebook.com/profile.php
• LinkedInlinkedin.com/company/probiotix-health

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ProBiotix Health